Mark Denison

Twelve current investigators at Vanderbilt University Medical Center and Vanderbilt University are on this year’s list of scientists whose papers have been cited the most frequently by other researchers. Read More

Vanderbilt research shows that the virus that causes COVID-19 can develop partial resistance to the antiviral drug remdesivir during infection of cultured cells in the laboratory by more than one mechanism.   Read More

An experimental coronavirus vaccine stimulated robust immune responses against SARS-CoV-2, the virus that causes COVID-19, and raised no serious safety concerns in an early-stage clinical trial. Read More

This week researchers at Vanderbilt University Medical Center (VUMC), the University of North Carolina at Chapel Hill and Gilead Sciences reported that remdesivir potently inhibited SARS-CoV-2, the virus which causes COVID-19, in human lung cell cultures and that it improved lung function in mice infected with the virus. Read More

Researchers at Vanderbilt University Medical Center are playing a key role in the development of a potential new antiviral drug to treat COVID-19. Read More

A new antiviral drug candidate inhibits a broad range of coronaviruses, including the SARS and MERS coronaviruses, a multi-institutional team of investigators reports this week in Science Translational Medicine. Read More

Understanding the role that host membrane modification plays in coronavirus replication is essential for developing novel approaches to block the viruses that cause SARS and MERS. Read More

A coronavirus protein is required for replication of the viral genome and may be a good treatment target for SARS and other diseases caused by coronaviruses. Read More

Collaborating researchers at the University of North Carolina and Vanderbilt University have found that accelerating the rate of mutations in the coronavirus responsible for deadly severe acute respiratory syndrome (SARS) cripples the virus’s ability to cause disease in animals. Read More